Issue of Equity

Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical company focused on neurodevelopmental disorders, announces the issue of 1,200,000 new ordinary shares of 10p each in the Company (”Ordinary Shares”) following the exercise of options granted to Professor Eric Hollander and Professor Mark Smith in March 2006. As a result, the Company’s issued share capital now consists of 32,736,697 ordinary shares of 10p each, with one voting right per share. The Company holds no ordinary shares in Treasury, therefore, the total number of voting rights in the Company is 32,736,697.

For further information please contact:

Neuropharm + 44 (0) 1372 371 171

Robert Mansfield , Chief Executive Officer

Graham Yeatman, Chief Financial Officer

Piper Jaffray Ltd. + 44 (0) 20 3142 8700

Neil Mackison , Rupert Winckler

Buchanan Communications + 44 (0) 20 7466 5000

Mark Court , Catherine Breen

Notes to Editors:

About Neuropharm

Neuropharm is a speciality pharmaceutical company focused on the development of medicines for the treatment and management of neurodevelopmental disorders. Please visit www.neuropharm.co.ukfor further information.